Breast Cancer Hub

Breast Cancer Hub


ODA-Expert Perspectives-204TNBC Bonus Content_960x800
Dr. Jason Mouabbi shares updates in breast cancer research from the 2023 San Antonio Breast Cancer Symposium.
Janie Metsker, RN, shares how to reframe the conversation in metastatic breast cancer to prioritize shared decision making.
real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer
Dr. Connie Visovsky shares self-management strategies for breast cancer treatment–associated peripheral neuropathy.


Dr. Eun-Ok shares her pioneering research using digital approaches to address racial/ethnic cancer survivorship disparities.
The FDA has granted approval to abemaciclib with endocrine therapy for treatment of adult patients with early breast cancer.
The FDA has granted approval to sacituzumab govitecan-hziy for treatment of patients with HR-positive breast cancer.
The FDA approved elacestrant for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated breast cancer.
i3 Health's educational activity has improved knowledge of treatment advances for metastatic triple-negative breast cancer.


Connie Visovsky shares her research regarding exercise as a self-management strategy for CIPN experienced by patients during treatment.
Jason Mouabbi, MD, answers frequently asked questions and debunks common myths surrounding breast cancer.
Molly MacDonald, Founder of Pink Fund, shares how the organization provides financial assistance for breast cancer patients.
Dr. Nicholas Robert explains the impacts of social determinants of health in triple-negative breast cancer treatment.